Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Drug Profile

Research programme: interleukin-4 therapeutics - Medicenna Therapeutics

Alternative Names: IL4-ECs; IL4-Empowered Cytokines; Interleukin-4 Empowered Cytokines™; MDNA 56; MDNA-57

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicenna Therapeutics
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 24 Oct 2017 Medicenna Therapeutics in-licenses patent for Interleukin-4 Superkines from Stanford University
  • 24 Oct 2017 Stanford University has patent protection for Interleukin-4 Superkines
  • 16 Mar 2017 Medicenna Therapeutics enter into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to develop fusion protein therapeutics targeting the IL 4 receptor and to advance preclinical development of Empowered Cytokines™ based on IL 4 and IL 13 Superkine™ platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top